British drug maker cuts earnings expectations

The Associated Press

Published: July 23, 2014 9:10 am
Earnings • GlaxoSmithKline had weak second quarter with lower sales of respiratory drugs.
This is an archived article that was published on sltrib.com in 2014, and information in the article may be outdated. It is provided only for personal research purposes and may not be reprinted.

London • Drug maker GlaxoSmithKline has cut its full-year earnings expectations as it says its second-quarter profits were hit by currency moves and a fall in sales of its respiratory drugs.

The company said Wednesday it expects 2014 earnings per share to be broadly similar to last year. It had previously forecast growth of between 4 and 8 percent.

GSK said second-quarter revenue fell 16 percent to 5.6 billion pounds ($9.5 billion) from 6.6 billion pounds in the same quarter in the previous year. Profit attributable to shareholders dropped from 1.05 billion pounds a year earlier to 654 million pounds.

The firm, which remains troubled by a high-profile bribery investigation in China, said sales there were down 20 percent.

© Copyright 2024 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.